Table 2.
Use of vitamin D supplementation in different countries by exclusive breast-feeding status when the child was 5 months old: TRIGR (Trial to Reduce IDDM in the Genetically at Risk) study, 2002–2007
| Region† | Exclusive breast-feeding | n | 0–2 weeks (%) | 2 weeks–1 month (%) | 1–2 months (%) | 2–3 months (%) | 3–4 months (%) | 4–5 months (%) | 5–6 months (%) |
|---|---|---|---|---|---|---|---|---|---|
| Northern Europe | ⩾5 months | 33 | 24·2 | 78·8 | 93·9 | 97·0 | 100·0 | 100·0 | 100·0 |
| <5 months | 488 | 23·6 | 84·6 | 94·2 | 97·4 | 97·6 | 98·0 | 97·0 | |
| Central Europe I | ⩾5 months | 76 | 47·4 | 96·1 | 100·0 | 97·3 | 97·3 | 98·7 | 97·3 |
| <5 months | 241 | 46·4 | 90·1 | 94·7 | 97·3 | 96·0 | 96·9 | 97·3 | |
| Central Europe II | ⩾5 months | 33 | 60·6 | 81·8 | 87·9 | 90·9 | 90·9 | 90·9 | 93·5 |
| <5 months | 151 | 51·0 | 80·5 | 87·2 | 86·4 | 83·0 | 82·8 | 80·3 | |
| Southern Europe | ⩾5 months | 9 | 11·1 | 33·3 | 33·3 | 44·4 | 44·4 | 44·4 | 55·6 |
| <5 months | 105 | 32·7 | 64·9 | 71·1 | 71·3 | 74·5 | 76·3 | 79·6 | |
| USA | ⩾5 months | 43 | 0·0 | 0·0 | 0·0 | 0·0 | 0·0 | 0·0 | 2·3 |
| <5 months | 350 | 0·3 | 0·9 | 1·2 | 1·2 | 1·7 | 1·8 | 1·5 | |
| Canada | ⩾5 months | 31 | 54·8 | 75·9 | 71·0 | 77·4 | 74·2 | 67·7 | 71·0 |
| <5 months | 497 | 29·2 | 48·2 | 54·0 | 53·5 | 51·9 | 46·3 | 44·4 | |
| Australia | ⩾5 months | 17 | 0·0 | 0·0 | 0·0 | 0·0 | 0·0 | 0·0 | 0·0 |
| <5 months | 85 | 1·2 | 0·0 | 0·0 | 1·2 | 0·0 | 1·2 | 1·2 |
IDDM, insulin-dependent diabetes mellitus.
†The following regions were included: Northern Europe (Finland and Sweden); Central Europe I (Czech Republic, Estonia, Hungary and Poland; transition economies); Central Europe II (Germany, Luxembourg, the Netherlands and Switzerland); Southern Europe (Italy and Spain); the USA; Canada; and Australia.